Next Generation Centrifuge Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Next Generation Centrifuge Market Trends and Insights

Expansion of Cell and Gene Therapy Manufacturing

Cell and gene therapy manufacturing has transformed centrifugation from a routine laboratory activity into a controlled production process. Cell isolation, density-gradient fractionation, spinoculation, post-transduction washing, and final formulation require defined centrifuge settings under GMP controls. A 2025 study reported transduction efficiency of 83.4% using an automated closed-system centrifuge, compared with 72.8% for conventional bag centrifugation and 35.7% for static incubation.^[1] These performance differences can affect yield and batch acceptance at commercial scale, supporting demand in the next-generation centrifuge market for systems with validated parameters, electronic records, and closed tubing connections.

Growth of High-Throughput Molecular Diagnostics and Omics Workflows

Centrifugal microfluidics is expanding the application of centrifugation in diagnostic workflows. A single drive unit can perform fluid movement, separation, and mixing across more than 30 sample wells, reducing manual pipetting in complex processes. A 2025 study described a centrifugal microfluidic chip that integrated 30-plex nucleic acid purification and ELISA on a single lab-on-disc platform. This integration supports demand for compatible drive systems and diagnostic cartridges in the next-generation centrifuge market.^[2]

Adoption of Automated, Connected, and Traceable Laboratory Workflows

Laboratory automation is changing centrifuge selection criteria in high-volume settings. Buyers increasingly require serial communication, programmable rotor positioning, rapid lid cycles, and LIMS connectivity to integrate centrifuges into automated laboratory cells. Automation-ready systems reduce manual handoffs and strengthen workflow traceability. As a result, the Next Generation Centrifuge Market is shifting toward connected platforms rather than standalone instruments. Regulated laboratories require electronic audit trails and traceable component identification to meet FDA 21 CFR Part 11 and EU Annex 11 requirements. Eppendorf introduced the SpinPro 6R in March 2026, featuring CO2-based ACT 2.0 cooling, RFID rotor recognition, LIMS connectivity, and QuickLock Pro lids. These capabilities support documented workflows across pharmaceutical, biotechnology, and research applications. Validated connectivity can also reduce competition from the refurbished equipment channel, as regulated buyers prioritize compliance over lower acquisition costs.

Increasing Use of Closed and Single-Use Separation Systems in Bioprocessing

Single-use centrifuge systems eliminate cleaning-in-place and sterilization-in-place requirements between production runs. In biopharmaceutical manufacturing, these activities previously required 6 to 12 hours of downtime. Eliminating these steps improves primary clarification productivity and reduces turnaround time. GEA introduced the kytero 10 in 2025 as a single-use disk-stack centrifuge for 1 to 10-liter cell harvesting, supporting continuous perfusion processes in cell and gene therapy and alternative protein production.

A 2025 evaluation assessed a single-use disk-stack centrifuge for monoclonal antibody harvest at scales of up to 5,000 liters. The study found product quality comparable to conventional stainless-steel centrifuges across SE-HPLC, icIEF, HCP, and rDNA profiles, along with improved turbidity and LDH reduction. These findings validate the technology for commercial-scale monoclonal antibody manufacturing.^[3] Single-use systems also increase demand for accessories and consumable assemblies, placing pressure on conventional equipment suppliers as buyers adopt disposable-centered operating models.

High Capital Cost and Total Cost of Ownership

Advanced floor-standing centrifuges for GMP bioprocessing require acquisition costs ranging from USD 80,000 to more than USD 300,000. Over a 10-year operating life, rotor replacements, preventive maintenance, recertification, validated consumable kits, and energy consumption can raise total ownership costs to more than three times the list price. These high costs limit equipment upgrades among smaller laboratories and emerging organizations.

Large CDMOs and pharmaceutical manufacturers can absorb these expenses more readily, while academic spinouts and early-stage cell therapy developers may retain existing equipment longer. Qualification and process validation add further costs, as IQ, OQ, and PQ documentation for a GMP-grade installation can require three to six months of engineering work. Cost-sensitive buyers may select certified pre-owned systems, available at 30-50% of new-instrument prices, for standard separation requirements.

Long Replacement Cycles and Availability of Refurbished Equipment

A well-maintained laboratory centrifuge typically has an operational life of 8-12 years, limiting annual demand for new equipment in North America and Western Europe, where installed bases are dense. Authorized repair networks further extend equipment life. Certified pre-owned systems, resold with calibration certificates, updated operating software, and rotor-integrity documentation, compete directly with new instruments in academic, clinical, and early-stage pharmaceutical settings.

Third-party brokers, rather than manufacturer distributors, often operate the refurbished equipment channel, making its impact less visible in manufacturer sales reporting and win-loss reviews. Users may also wait for full asset depreciation before replacing equipment, slowing technology transitions across installed bases. This can delay the adoption of natural-refrigerant platforms, despite their compliance and energy-efficiency benefits.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Consumables Growth Is Reshaping the Revenue Mix

Equipment is projected to account for 76.12% of the Next Generation Centrifuge Market in 2025. Purchases of clinical-grade and GMP-certified systems by hospitals, CDMOs, and pharmaceutical companies support this position. Both floor-standing and benchtop formats contribute to equipment revenue. Service and lifecycle support are also becoming increasingly important as suppliers offer multiyear service contracts. These contracts generate recurring revenue and help suppliers retain key accounts, resembling the reagent-rental models used in in-vitro diagnostics.

Accessories and consumables are forecast to grow at a CAGR of 9.22% through 2031. Single-use separation sets, validated tubeset assemblies, and RFID-chipped rotor adapters often require replacement after each production batch, helping prevent cross-contamination in cell therapy cleanrooms. Instant Systems' CentriLoc cell therapy tubes provide an example of validated tubeset assemblies. In high-utilization GMP operations, consumables revenue can exceed the initial equipment purchase. Suppliers are therefore competing through validated consumables ecosystems in addition to instrument performance.

By Model: Floor-Standing Centrifuge Demand Follows Bioprocessing Scale-Up

Benchtop centrifuges are projected to hold 61.30% of the Next Generation Centrifuge Market in 2025. Their position reflects widespread use across clinical laboratories, research institutes, and biotechnology discovery operations. Footprint, versatility, and lower upfront costs remain key selection criteria. In 2025, Haier Biomedical is expected to launch the LX-155T750R, a 3-liter refrigerated system that reaches speeds of 15,500 rpm and 26,322 × g for molecular biology, clinical research, and biobanking workflows. 

Floor-standing centrifuges are forecast to grow at a CAGR of 8.67% through 2031, driven by the shift toward larger-scale, continuous-duty separation in commercial bioprocessing. In April 2025, Thermo Fisher is expected to launch the BIOS A and 16 centrifuges featuring GreenCool Technology. The company reports that the systems will have a global warming potential of 1 and consume 15% less energy than the preceding systems. Ultracentrifuges and microcentrifuges remain specialized categories for virology, nanoparticle characterization, and subcellular fractionation applications requiring speeds above 100,000 × g.

By Application: Diagnostics Supports Volume While Cell Therapy Drives Premium Demand

Clinical diagnostics are projected to account for 39.67% of the Next Generation Centrifuge Market in 2025. Hospital networks and commercial reference laboratories support this volume through serum separation, urinalysis, blood processing, and nucleic acid extraction. These workflows are high frequency and generally non-discretionary. Biotechnology and pharmaceutical research represent the second-largest application segment, encompassing plasmid DNA preparation, exosome isolation, viral vector purification, and protein fractionation. These applications require programmable g-force profiles and controlled temperatures over extended run times.

Cell and gene therapy is forecast to grow at a CAGR of 9.78% through 2031. GMP-certified systems with closed tubing, electronic audit trails, and spinoculation capabilities can command premium prices in this application. Blood component separation and bioprocessing continue to support demand from transfusion centers and bioreactor harvest operations. Although validated equipment configurations can slow replacement cycles, they sustain consumables attachment rates.

By End User: Biotechnology and Pharmaceutical Companies Support the Premium Tier

Hospitals and diagnostic laboratories represented 46.75% of the Next Generation Centrifuge Market share in 2025, supported by routine clinical centrifugation requirements and high sample volumes. Academic and research institutes remain important end users, although grant-funded purchasing and shared-equipment models can slow replacement cycles. Blood banks and transfusion centers require ergonomic, traceable blood-bag centrifuges.

Biotechnology and pharmaceutical companies are forecast to grow at a 10.45% CAGR through 2031. Commercial-stage cell therapy manufacturers are bringing separation workflows in-house to maintain per-batch quality control, supporting demand for automation-compatible and LIMS-connected systems. Samsung Biologics secured a USD 262 million manufacturing contract in 2026 and is expanding its Songdo campus from 180,000 liters to 720,000 liters by 2032, requiring centrifuge fleets for clarification, washing, and formulation.

Geography Analysis

North America is projected to hold a 38.10% share of the Next Generation Centrifuge Market in 2025. The United States has a large regulated base of approved cell and gene therapies, supported by hospitals, reference laboratories, and biopharmaceutical networks. Canada is expanding biomanufacturing capacity, while Mexico is strengthening clinical diagnostics and pharmaceutical manufacturing capabilities.

North American growth through 2031 is forecast to remain steady, supported by compliance-driven replacements and cell therapy investments. In Europe, Regulation (EU) 2024/573 is driving equipment replacement as quota reductions for high-global-warming-potential refrigerants begin in 2025. Thermo Fisher Scientific introduced the Cryofuge, BIOS, and LYNX lines to meet EU F-gas and U.S. EPA SNAP requirements, with Germany, the United Kingdom, and France leading demand.

Asia-Pacific is forecast to record an 8.95% CAGR through 2031, the highest among regional markets. China, South Korea, Japan, and India are expanding biopharmaceutical capacity, while AGC Biologics has a commercial agreement for production at its Yokohama site. TheraNym Biologics announced a USD 150-175 million investment in a mammalian cell culture biologic drug substance facility for Merck. The Middle East and Africa and South America continue to benefit from healthcare investment, regulatory modernization, laboratory consolidation, and biopharmaceutical activity.